LTR Pharma Ltd (LTP) - Total Liabilities
Based on the latest financial reports, LTR Pharma Ltd (LTP) has total liabilities worth AU$700.57K AUD (≈ $495.70K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore LTR Pharma Ltd operating cash flow efficiency to assess how effectively this company generates cash.
LTR Pharma Ltd - Total Liabilities Trend (2021–2025)
This chart illustrates how LTR Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. See LTR Pharma Ltd (LTP) net assets for net asset value and shareholders' equity analysis.
LTR Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of LTR Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Helbor Empreendimentos S.A
SA:HBOR3
|
Brazil | R$3.78 Billion |
|
Flanigans Enterprises Inc
NYSE MKT:BDL
|
USA | $62.29 Million |
|
MODISON LIMITED
NSE:MODISONLTD
|
India | Rs1.27 Billion |
|
Nanexa AB
ST:NANEXA
|
Sweden | Skr36.61 Million |
|
SEOJEON ELECTRIC MACHINERY Co.Ltd
KQ:189860
|
Korea | ₩30.48 Billion |
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
USA | $40.10 Million |
|
Acorn Capital Investment Fund Ltd
AU:ACQ
|
Australia | AU$7.92 Million |
|
Lunnon Metals Ltd
AU:LM8
|
Australia | AU$1.16 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down LTR Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LTP stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 45.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LTR Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LTR Pharma Ltd (2021–2025)
The table below shows the annual total liabilities of LTR Pharma Ltd from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$700.57K ≈ $495.70K |
+63.48% |
| 2024-06-30 | AU$428.54K ≈ $303.22K |
+1915.71% |
| 2023-06-30 | AU$21.26K ≈ $15.04K |
-95.53% |
| 2022-06-30 | AU$475.91K ≈ $336.74K |
+2.68% |
| 2021-06-30 | AU$463.50K ≈ $327.96K |
-- |
About LTR Pharma Ltd
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australi… Read more